Radiotherapy for Rectal Cancer: How Much is Enough?

Area of Science:

• Oncology
• Radiation Oncology
• Surgical Oncology

Background:

• Resection was the primary treatment for nonmetastatic rectal cancer historically.
• Radiotherapy is now crucial for locally advanced rectal cancer, with two main approaches: hyperfractionated chemoradiotherapy and short-course radiation.
• Both methods are integrated into total neoadjuvant therapy (TNT) regimens.

Purpose of the Study:

• To compare the efficacy of hyperfractionated chemoradiotherapy and short-course radiation within TNT for locally advanced rectal cancer.
• To evaluate local recurrence rates and complete response rates for different radiotherapy modalities.
• To inform the selection of optimal radiation strategies in rectal cancer treatment.

Main Methods:

• Review and synthesis of existing data on hyperfractionated chemoradiotherapy and short-course radiation in TNT regimens.
• Analysis of outcomes including local control, complete response rates, and patient convenience.
• Identification of the need for direct comparative studies.

Main Results:

• Both chemoradiotherapy and short-course radiation in TNT achieve excellent local control and high complete response rates.
• Short-course radiation offers cost and convenience benefits.
• Emerging data suggest potential superiority of chemoradiotherapy in complete response and local recurrence rates.

Conclusions:

• Both radiotherapy modalities show promise in TNT for locally advanced rectal cancer, with 'watch and wait' protocols yielding encouraging results.
• Direct comparative trials of short-course radiotherapy versus chemoradiotherapy within the TNT framework are essential.
• Such comparisons will clarify the optimal radiation regimen for improving treatment outcomes in locally advanced rectal cancer.